[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20071249A1 - Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico - Google Patents

Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico

Info

Publication number
PE20071249A1
PE20071249A1 PE2007000135A PE2007000135A PE20071249A1 PE 20071249 A1 PE20071249 A1 PE 20071249A1 PE 2007000135 A PE2007000135 A PE 2007000135A PE 2007000135 A PE2007000135 A PE 2007000135A PE 20071249 A1 PE20071249 A1 PE 20071249A1
Authority
PE
Peru
Prior art keywords
hydroxy
methyl
ester
metoxyphenylcarbamoyl
piperidin
Prior art date
Application number
PE2007000135A
Other languages
English (en)
Inventor
Reshma Chudasama
Andrew Kennedy
Leanda Jane Kindon
Frank Patrick Mallet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20071249A1 publication Critical patent/PE20071249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA SAL DE ACIDO SUCCINICO DE 1-[2-(2-CLORO-4-{[(R)-2-HIDROXI-2-(8-HIDROXI-2-OXO-1,2-DIHIDROQUINOLIN-5-IL)ETILAMINO]METIL}-5-METOXIFENILCARBAMOIL)ETIL]PIPERIDIN-4-IL ESTER DEL ACIDO BIFENIL-2-ILCARBAMICO, EN FORMA CRISTALINA EN ESTADO SOLIDO DENOMINADO FORMA 1, CARACTERIZADO POR PRESENTAR UN PUNTO DE FUSION ENTRE 170 Y 180 ºC; UN PATRON DE DIFRACCION DE POLVO DE RAYOS X QUE TIENE PICOS EXPRESADOS EN 2? DE 5,0 Y 10,0 ± 0,3; UN ESPECTRO DE ABSORCION DE INFRARROJOS CON BANDAS DE ABSORCION DE 3265, 2832, 1735, 1718, 1679, 1669, 1591, 1540, 1518 cm-1, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMINIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA QUE ADICIONALMENTE PUEDE COMPRENDER UN AGENTE ANTIINFLAMATORIO ESTEROIDEO TAL COMO S-FLUOROMETIL ESTER DEL ACIDO 6a,9a-DIFLUORO-17a-[(2-FURANILCARBONIL)OXI-11ß-HIDROXI-16a-METIL-3-OXOANDROSTA-1,4-DIENO-17ß-CARBOTIOICO, SIENDO UTIL EN EL TRATAMIENTO DE TRASTORNO PULMONAR
PE2007000135A 2006-02-10 2007-02-08 Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico PE20071249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Publications (1)

Publication Number Publication Date
PE20071249A1 true PE20071249A1 (es) 2008-01-16

Family

ID=36119909

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000135A PE20071249A1 (es) 2006-02-10 2007-02-08 Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico
PE2010000996A PE20110120A1 (es) 2006-02-10 2007-02-08 Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2010000996A PE20110120A1 (es) 2006-02-10 2007-02-08 Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico

Country Status (33)

Country Link
US (1) US7960551B2 (es)
EP (1) EP1981872B1 (es)
JP (1) JP5616021B2 (es)
KR (1) KR101488691B1 (es)
CN (1) CN101379057B (es)
AR (2) AR059409A1 (es)
AU (1) AU2007213767B2 (es)
BR (1) BRPI0707559B8 (es)
CA (1) CA2641769C (es)
CR (1) CR10227A (es)
CY (1) CY1119238T1 (es)
DK (1) DK1981872T3 (es)
EA (1) EA016580B1 (es)
ES (1) ES2640226T3 (es)
GB (1) GB0602778D0 (es)
HR (1) HRP20171304T1 (es)
HU (1) HUE034315T2 (es)
IL (1) IL193103A (es)
JO (1) JO3389B1 (es)
LT (1) LT1981872T (es)
MA (1) MA30273B1 (es)
MY (1) MY153656A (es)
NO (1) NO341343B1 (es)
NZ (1) NZ570242A (es)
PE (2) PE20071249A1 (es)
PL (1) PL1981872T3 (es)
PT (1) PT1981872T (es)
SG (1) SG169404A1 (es)
SI (1) SI1981872T1 (es)
TW (1) TWI401251B (es)
UA (1) UA100364C2 (es)
WO (1) WO2007090859A1 (es)
ZA (1) ZA200806782B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101720154B1 (ko) 2009-04-14 2017-03-27 글락소 그룹 리미티드 바이페닐­2­일카르밤산 에스테르의 제조 방법
TR201903556T4 (tr) 2009-04-23 2019-04-22 Theravance Respiratory Co Llc Muskarinik reseptör antagonisti ve beta 2 adrenerjik reseptör agonisti aktivitesine sahip diamid bileşikleri.
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
CA2842276C (en) * 2011-08-02 2020-11-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
MA38260B1 (fr) * 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
DE69327583T2 (de) 1992-03-31 2000-05-31 Glaxo Group Ltd., Greenford Substituierte phenylcarbamate und phenylharnstoffe, ihre herstellung und ihre verwendung als 5-ht4-antagonisten
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (fr) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
AU7145996A (en) 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
EP1086066A4 (en) 1998-06-08 2001-08-08 Advanced Medicine Inc MUSCARINIC RECEPTOR ANTAGONISTS
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
CA2392028C (en) 1999-12-07 2009-08-18 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
KR20030031907A (ko) 2000-06-05 2003-04-23 알타나 파마 아게 β-2-아드레날린 수용체 작동물질로서 뿐만 아니라ＰＤＥ4-억제제로서 효과적인 화합물
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
CN1646527A (zh) 2002-04-12 2005-07-27 贝林格尔英格海姆法玛两合公司 包含β模拟剂(BETAMIMETICS)及新颖抗胆碱酯酶的药物
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
DE602004021921D1 (de) * 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
DE602004021959D1 (de) * 2003-11-21 2009-08-20 Theravance Inc Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
EP1833822A2 (en) * 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物

Also Published As

Publication number Publication date
JP2009526018A (ja) 2009-07-16
IL193103A (en) 2013-06-27
EP1981872A1 (en) 2008-10-22
US7960551B2 (en) 2011-06-14
HRP20171304T1 (hr) 2017-10-20
WO2007090859A1 (en) 2007-08-16
HUE034315T2 (en) 2018-02-28
JO3389B1 (ar) 2019-03-13
SG169404A1 (en) 2011-03-30
NZ570242A (en) 2011-09-30
LT1981872T (lt) 2017-09-11
CR10227A (es) 2008-10-29
CY1119238T1 (el) 2018-02-14
EA016580B1 (ru) 2012-06-29
EP1981872B1 (en) 2017-06-21
PE20110120A1 (es) 2011-03-08
MA30273B1 (fr) 2009-03-02
MY153656A (en) 2015-03-13
UA100364C2 (xx) 2012-12-25
SI1981872T1 (sl) 2017-10-30
GB0602778D0 (en) 2006-03-22
JP5616021B2 (ja) 2014-10-29
KR20080114723A (ko) 2008-12-31
BRPI0707559A8 (pt) 2019-01-29
NO341343B1 (no) 2017-10-16
ZA200806782B (en) 2009-10-28
BRPI0707559A2 (pt) 2011-05-10
CA2641769A1 (en) 2007-08-16
EA200801691A1 (ru) 2009-02-27
BRPI0707559B8 (pt) 2021-05-25
AR104288A2 (es) 2017-07-12
KR101488691B1 (ko) 2015-02-02
ES2640226T3 (es) 2017-11-02
CA2641769C (en) 2014-02-04
PT1981872T (pt) 2017-09-13
BRPI0707559B1 (pt) 2021-01-12
TW200800948A (en) 2008-01-01
CN101379057B (zh) 2013-02-13
AU2007213767A1 (en) 2007-08-16
DK1981872T3 (en) 2017-09-11
CN101379057A (zh) 2009-03-04
TWI401251B (zh) 2013-07-11
IL193103A0 (en) 2009-02-11
NO20083425L (no) 2008-09-09
PL1981872T3 (pl) 2017-11-30
AR059409A1 (es) 2008-04-09
AU2007213767B2 (en) 2012-04-26
US20070281971A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
PE20071249A1 (es) Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
PH12018550205A1 (en) Synergistic antifungal compositions and methods thereof
CL2010000935A1 (es) Compuestos derivados de niacina unida a un acido graso; composicion farmaceutica que los comprende; y su uso para tratar una enfermedad metabolica tal como hipertrigliceridemia, hipercolesterolemia, diabetes tipo 2 y retinopatia diabetica.
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
EP2397403A3 (en) Morphing control surface transition
CL2013002593A1 (es) Forma cristalina a1 de la sal clorhidrato del compuesto 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una enfermedad o trastorno tal como cancer, angiogenesis, dolor, trastorno pulmonar y un trastorno del snc.
PE20140255A1 (es) Tableta dispersable en forma oral
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
UY30394A1 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
EP3816267A4 (en) ISOBUTTERIC ACID ESTER COMPOUND WITH ACETOXY GROUP AT THE SS POSITION, PERFUME COMPOSITION AND USE AS PERFUME
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
EP3816266A4 (en) SS-HYDROXYISOBUTIC ACID ESTER COMPOUND, PERFUME COMPOSITION AND USE AS A PERFUME
EP2212325A4 (en) 2-ARYLMETHYLAZETIDINCARBAPENEM-3-CARBOXYLENE DERTERIVATE OR SALT, METHOD FOR THE PRODUCTION THEREOF AND THEREOF COMPRISING PHARMACEUTICAL COMPOSITION
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2017165822A8 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CL2009001328A1 (es) Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor.
EP3816270A4 (en) ISOBUTYRIC ACID ESTER COMPOUND WITH FORMYLOXY GROUP IN POSITION ?, COMPOSITION OF PERFUMED MATERIAL AND USE AS PERFUMED MATERIAL
BR112012015170A8 (pt) Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor
CL2008000026A1 (es) Compuestos derivados de quinolona; composicion farmaceutica que contiene dichos compuestos; metodo de preparacion de la composicion farmaceutica; y su uso como agente antibacteriano.
CL2009001330A1 (es) Compuestos derivados de ciano-3-oxoisoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno de dolor.

Legal Events

Date Code Title Description
FC Refusal